

Freedom of Information Request	FOI 21-092	11 <sup>th</sup> March 2021
--------------------------------	------------	-----------------------------

**I am analysing the usage of anti-VEGF treatments for eye conditions. I would greatly appreciate if you could answer three questions:**

**1. For the 4-month period from September to December 2020, how many patients has your trust treated with the following anti-VEGF treatments:**

- Aflibercept
- Bevacizumab
- Brolucizumab
- Dexamethasone
- Fluocinolone acetonide
- Ranibizumab

**2. Within your trust how many intra-vitreous injections/implants of each of the following treatments have been used in the four-month period from September to December 2020:**

- Aflibercept
- Bevacizumab
- Brolucizumab
- Dexamethasone
- Fluocinolone
- Ranibizumab

**3. If your trust is able to identify intra-vitreous injections/implants by eye condition, please provide the number of injections/implants used in the four-month period from September to December 2020 for each of the following conditions:**

**Wet Age Related Macular Degeneration (wAMD)**

- Aflibercept
- Bevacizumab
- Brolucizumab
- Dexamethasone
- Ranibizumab

**Diabetic Macular Oedema (DMO)**

- Aflibercept
- Bevacizumab
- Dexamethasone
- Ranibizumab

**Retinal Vein Occlusion - Central (CRVO) or Branch (BRVO)**

- Aflibercept

- **Bevacizumab**
- **Dexamethasone**
- **Ranibizumab**

Aflibercept Intravitreal Injection	4mg in 0.1ml	1 x syringe	2477
Ranibizumab Intravitreal Injection	10mg in 1ml	1 PF Syr	1050
Dexamethasone Intravitreal Implant	700 micrograms	1 implant	9
Fluocinolone Acetonide Intravitreal implant	190 micrograms	1 implant	1